Navigation Links
Hepatitis C treatment is cost-effective for the US prison population
Date:10/20/2008

Treating all U.S. prisoners who have hepatitis C with the standard therapy of pegylated-interferon and ribavirin would be cost-effective, says a new study in the November issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience (www.interscience.wiley.com).

U.S. prisons incarcerate more than 2 million inmates each year, and between 12 and 31 percent of them are infected with chronic hepatitis C (HCV), mostly related to high rates of intravenous drug use. The current standard treatment for HCV has been shown to be cost-effective in the general population and the Federal Bureau of Prisons recommends HCV treatment for those who meet the AASLD's criteria for treatment, as long as therapy is likely to be completed. However, each state adopts its own set of treatment guidelines, and many prisoners do not ultimately get treated.

Proponents for treatment argue that we have an ethical duty to provide prisoners with the best medical practices available, and treating HCV could reduce new infections as well as future medical expenses from advanced liver disease. Opponents point out that treatment is expensive and must be paid for by taxpayers, while many non-imprisoned HCV patients who don't have health insurance are denied access to this care.

Researchers, led by Sammy Saab of the David Geffen School of Medicine at UCLA, sought to determine if HCV treatment would be cost-effective in the male prison population (men make up over 87 percent of U.S. prisoners). They examined published literature for relevant studies and constructed a decision analysis model employing Markov simulation, using the generally accepted cost-effectiveness threshold of $50,000 per quality-adjusted life years.

"Our model found that treatment was cost-saving for prisoners of all age ranges and genotypes when liver biopsy was not a prerequisite to starting antiviral therapy," they report. "In other words, treatment resulted in both decreased costs and improved quality of life." Treatment was also cost-saving in most situations that included a pre-treatment liver biopsy.

The authors had not expected treatment to be cost-effective, because of the high re-infection rates and non-liver mortality rates in the prison population. However, they write, "our results demonstrate that pegylated-interferon and ribavirin is cost-saving in the prison population, both in strategies with and without biopsy. Incorporating a pre-treatment liver biopsy may be the most cost-effective approach, however, as one could potentially exclude certain patients with no fibrosis from therapy."

"If the decision to treat is based on pharmacoeconomic measures," the authors conclude, "the results of our analysis suggest that treatment is cost-saving and should not be withheld in U.S. prisoners with hepatitis C."

Since the efficacy of treatment would be diminished by relapse to injection drug use and re-infection, treatment should be coupled with educational and substance abuse programs, they suggest. And because mental illness is widespread in the prison population, and can often be exacerbated by treatment, careful mental health screening and follow-up would be required.


'/>"/>

Contact: Sean Wagner
swagner@wiley.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Existing anti-obesity drugs may be effective against flu, hepatitis and HIV
2. Majority of children vaccinated against hepatitis B not at increased risk of MS
3. How to select anti-hepatitis B virus agents for drug-resistance patients?
4. The prevalence of hepatitis B virus infection in inflammatory bowel disease patients
5. A potential approach to treatment of hepatitis B virus infection
6. New approach, old drug show promise against hepatitis C, Stanford research shows
7. Early treatment is key to combating hepatitis C virus
8. New treatment therapy helps inhibit hepatitis C
9. Liver damage in hepatitis C patients could be treated with warfarin, says study
10. Study Disproves Belief That Hepatitis C Blunts HIV Drugs
11. Hepatitis B Foundation Sponsors Two-Day Educational Conference for Children and Adults at Risk for Deadly Liver Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Dental365 in Levittown opened just a few ... dentistry. Dental365 was established with the patient’s comfort and convenience in mind. ... high-quality, affordable dentistry while offering routine and walk-in emergency dental care 365 days a ...
(Date:5/4/2016)... ... May 05, 2016 , ... “Less than 15% of organizations nationwide can ... “As one of ten non-profit organizations to participate and complete the training, we are ... benefit is that for every $1 we invest in volunteer engagement, we can expect ...
(Date:5/4/2016)... ... May 04, 2016 , ... The manufacturer of the SOCKIT ... trainers to St. Jude Children’s Research Hospital to benefit families dealing with cancer ... designed to teach children how to kick a soccer ball correctly. The device ...
(Date:5/4/2016)... ... May 04, 2016 , ... NCPDP ... conference opened on Tuesday with Frank Luntz, sharing a dynamic, bi-partisan environmental scan ... a deep dive on NCPDP’s model solution to help stem the tide of ...
(Date:5/4/2016)... ... May 04, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... esteemed Quaker Ridge Golf Club in Scarsdale, New York on May 23, 2016 ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... JERUSALEM , May 4, 2016 ... University of Jerusalem announced today that it had ... BioTheryX, Inc. , developer of novel protein degradation ... the development and commercialization of drug candidates representing first-in-class ... the license were not disclosed. The novel ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Acute Myeloid Leukemia ...  report to their offering.       ... Acute Myeloid Leukemia Market and Competitive Landscape ... Myeloid Leukemia pipeline products, Acute Myeloid Leukemia ...
(Date:5/3/2016)... -- Research and Markets has announced the ... Market Outlook 2020" report to their offering. ... technology has improved significantly in past years due to ... coming years. Many cancer drugs have been developed by ... also expected to be developed with its help. They ...
Breaking Medicine Technology: